Last deal

$60M

Amount

Post-IPO Equity

Stage

07.11.2022

Date

3

all rounds

$451.87M

Total amount

date founded

Financing round

General

About Company
Marinus Pharmaceuticals develops and commercializes ganaxolone for neurological and psychiatric disorders.

Industry

Sector :

Subsector :

founded date

01.01.2003

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing ganaxolone, a neurosteroid, for the treatment of epilepsy and neuropsychiatric disorders. They have successfully completed Phase 2 trials for adult partial onset seizures and are currently conducting a Phase 2 proof of concept study for posttraumatic stress disorder (PTSD). The company aims to provide safe and convenient dosing options for both adult and pediatric patients in acute and chronic care settings. Marinus Pharmaceuticals was founded in 2003 and is headquartered in Branford, Connecticut.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
NONO

NONO

NoNO is a clinical-stage biotherapeutics company that develops pharmaceuticals for common health disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Toronto, ON, Canada

total rounds

2

total raised

$9.78M
Promentis Pharmaceuticals

Promentis Pharmaceuticals

Promentis Pharmaceuticals develops antipsychotic drugs to treat schizophrenia.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Milwaukee, WI, USA

total rounds

9

total raised

$63.85M
Aires Pharmaceuticals

Aires Pharmaceuticals

Aires Pharmaceuticals develops therapies to treat pulmonary disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

San Diego, CA, USA

total rounds

1

total raised

$20M
NRx Pharmaceuticals

NRx Pharmaceuticals

NRx Pharmaceuticals develops therapeutics for severe mental disorders and respiratory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

Wilmington, DE, USA

total rounds

11

total raised

$148.48M

Financials

Funding Rounds
13
3

Number of Funding Rounds

$451.87M

Money Raised

Their latest funding was raised on 07.11.2022. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
07.11.2022
$60M
04.04.2022
$1.23M

Sagard Healthcare Royalty Partners

Sagard Healthcare Royalty Partners is the royalty investment arm of Sagard Holdings, a private-equity firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Health Care

count Of Investments

3
Co-Investors
Investors
8
3

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B, Series C
No
Venture - Series Unknown

Sagard Healthcare Royalty Partners

Sagard Healthcare Royalty Partners is the royalty investment arm of Sagard Holdings, a private-equity firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Health Care

count Of Investments

3
Raja Manchanda

Raja Manchanda

Partner

current job

Sagard
Sagard
Foundation Medical Partners

Foundation Medical Partners

Foundation Medical Partners is a healthcare technology venture capital firm in the US.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Norwalk, CT, USA

count Of Investments

33

count Of Exists

13
RMI Partners

RMI Partners

RMI Partners is a venture capital firm that focuses on investing in innovative biopharmaceutical products and medical technologies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Moscow, Russia

count Of Investments

26

count Of Exists

4

People

Founders
1
Harry H. Penner
Harry H. Penner

Harry H. Penner

Mr. Penner is Founder, Chairman and Chief Executive Officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new biotechnology companies founded in September 2001. Mr. Penner is a Founder of New Haven Pharmaceuticals (of which he is Chairman and Chief Executive Officer), Prevention Pharmaceuticals, Affinimark Technologies, Rib-X Pharmaceuticals, RxGen, MAK Scientific, and Celldex Therapeutics. He was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation from 1993 to 2001. From 1985 to 1993 he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chair of Connecticut United for Research Excellence, and as Chair of the Connecticut Board of Governors of Higher Education. He currently serves on the Boards Rib-X, New Haven Pharmaceuticals, Prevention Pharmaceuticals, and Affinimark. Mr. Penner holds a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.

current job

Nascent BioScience LLC.

organization founded

10

Harry H. Penner

Employee Profiles
20

Romy Nocera

Director, scientific and medical education and communication

Martha Manning

Martha Manning

Vice President, General Counsel, and Corporate Secretary

Jason Balderson

Senior clinical trial manager

Alex Aimetti

Vp, scientific affairs

Achim Schultze

Director of product development

Scott Braunstein

Scott Braunstein

Chief Executive Officer

Julia Tsai

Vice president clinical development

Christopher M. Cashman

Christopher M. Cashman

Chairman of the Board & CEO

Activity

Recent News
17
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week